These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8776562)

  • 1. Improvement of corneal sensation and tear dynamics in diabetic patients by oral aldose reductase inhibitor, ONO-2235: a preliminary study.
    Fujishima H; Shimazaki J; Yagi Y; Tsubota K
    Cornea; 1996 Jul; 15(4):368-75. PubMed ID: 8776562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of corneal fluorescein staining in post cataract surgery of diabetic patients by an oral aldose reductase inhibitor, ONO-2235.
    Fujishima H; Tsubota K
    Br J Ophthalmol; 2002 Aug; 86(8):860-3. PubMed ID: 12140204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of abnormal corneal epithelial cell morphologic characteristics and reduced corneal sensitivity in diabetic patients by aldose reductase inhibitor, CT-112.
    Hosotani H; Ohashi Y; Yamada M; Tsubota K
    Am J Ophthalmol; 1995 Mar; 119(3):288-94. PubMed ID: 7872388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discoveries in research on diabetic keratopathy.
    Cisarik-Fredenburg P
    Optometry; 2001 Nov; 72(11):691-704. PubMed ID: 12363257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in corneal sensation, epithelial damage, and tear function after descemet stripping automated endothelial keratoplasty.
    Hirayama Y; Satake Y; Hirayama M; Shimazaki-Den S; Konomi K; Shimazaki J
    Cornea; 2013 Sep; 32(9):1255-9. PubMed ID: 23860426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications.
    Kador PF; Kinoshita JH; Sharpless NE
    J Med Chem; 1985 Jul; 28(7):841-9. PubMed ID: 3925146
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of an aldose reductase inhibitor on esophageal dysfunction in diabetic patients.
    Kinekawa F; Kubo F; Matsuda K; Fujita Y; Kobayashi M; Funakoshi F; Uchida N; Watanabe S; Tomita T; Uchida Y; Kuriyama S
    Hepatogastroenterology; 2005; 52(62):471-4. PubMed ID: 15816460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of topical aldose reductase inhibitor CT-112 on corneal sensitivity of diabetic rats.
    Hosotani H; Ohashi Y; Kinoshita S; Matsumoto T; Awata T
    Curr Eye Res; 1996 Oct; 15(10):1005-7. PubMed ID: 8921238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats.
    Yoshida T; Nishioka H; Yoshioka K; Nakano K; Kondo M; Terashima H
    Diabetes; 1987 Jan; 36(1):6-13. PubMed ID: 3025043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac sympathetic neuropathy and effects of aldose reductase inhibitor in streptozotocin-induced diabetic rats.
    Kurata C; Okayama K; Wakabayashi Y; Shouda S; Mikami T; Tawarahara K; Sugiyama T
    J Nucl Med; 1997 Nov; 38(11):1677-80. PubMed ID: 9374332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of aldose reductase inhibitor on corneal epithelial barrier function in galactose-fed dogs.
    Kubo E; Mori K; Kobayashi T; Takahashi Y; Yokoi N; Kinoshita S; Kasahara T; Yonezawa H; Akagi Y
    J Ocul Pharmacol Ther; 1998 Apr; 14(2):181-90. PubMed ID: 9572544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of an aldose reductase inhibitor, ONO-2235, insulin and their combination on the altered responsiveness to the nerve stimulation and agonists of the isolated atria of diabetic rats.
    Hashimoto H; Satoh N; Takiguchi Y; Nakashima M
    J Pharmacol Exp Ther; 1990 May; 253(2):552-7. PubMed ID: 2159998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of aldose reductase inhibitor on cutaneous nerve fiber length in diabetic patients.
    Yasuda H; Hirai A; Joko M; Terada M; Kawabata T; Maeda K; Haneda M; Kashiwagi A; Maeda T; Kikkawa R
    Diabetes Care; 2000 May; 23(5):705. PubMed ID: 10834436
    [No Abstract]   [Full Text] [Related]  

  • 14. [Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement].
    Shimada H; Miki T; Kyogoku I; Kawagishi T; Inaba M; Okuno Y; Nishizawa Y; Morii H
    No To Shinkei; 1998 Sep; 50(9):817-20. PubMed ID: 9789304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of aldose reductase inhibitors for diabetic gastroenteropathy with constipation.
    Nakamura T; Okano R; Uchiyama H; Seo Y; Okuda S
    Intern Med; 1997 Jul; 36(7):479-83. PubMed ID: 9240496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of aldose reductase inhibitor and vitamin B12 on myocardial uptake of iodine-123 metaiodobenzylguanidine in patients with non-insulin-dependent diabetes mellitus.
    Utsunomiya K; Narabayashi I; Tamura K; Nakatani Y; Saika Y; Onishi S; Kariyone S
    Eur J Nucl Med; 1998 Dec; 25(12):1643-8. PubMed ID: 9871096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tear production and corneal sensitivity in diabetes.
    Cousen P; Cackett P; Bennett H; Swa K; Dhillon B
    J Diabetes Complications; 2007; 21(6):371-3. PubMed ID: 17967709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan.
    Hotta N; Sakamoto N; Shigeta Y; Kikkawa R; Goto Y
    J Diabetes Complications; 1996; 10(3):168-72. PubMed ID: 8807467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Visual and tear function improvement after superficial phototherapeutic keratectomy (PTK) for mid-stromal corneal scarring.
    Dogru M; Katakami C; Miyashita M; Hida E; Uenishi M; Tetsumoto K; Kanno S; Nishida T; Yamanaka A
    Eye (Lond); 2000 Oct; 14 Pt 5():779-84. PubMed ID: 11116705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ɛ)-carboxymethyl lysine.
    Kawai T; Takei I; Tokui M; Funae O; Miyamoto K; Tabata M; Hirata T; Saruta T; Shimada A; Itoh H
    J Diabetes Complications; 2010; 24(6):424-32. PubMed ID: 19716319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.